Blood Purification最新文献

{"title":"Targeted Rapid Endotoxin Adsorption: Can We Bring Precision Medicine to Sepsis?","authors":"John A Kellum, Esha Kamaluddin, Debra Foster","doi":"10.1159/000544989","DOIUrl":"10.1159/000544989","url":null,"abstract":"<p><strong>Background: </strong>Historically, extracorporeal blood purification (EBP) treatment for sepsis was mainly used as an adjunctive therapy for the management of multiple organ failure rather than targeting the removal of toxins from the body that are contributing to the disease state. Approximately 10-15% of sepsis cases, or approximately one-third to half of patients with septic shock, exhibit high levels of endotoxin activity in their blood. Humans are exquisitely sensitive to endotoxin making endotoxic septic shock (ESS) particularly deadly. Today, we have an emerging class of EBP that is specific to endotoxin - targeted rapid endotoxin adsorption (TREA) - that can be used for the treatment of ESS.</p><p><strong>Summary: </strong>In septic patients, evidence for the use of hemofiltration and therapeutic plasma exchange, the two most prevalent forms of EBP, has been difficult to obtain. Additionally, broad-spectrum EBP therapies that target multiple solutes for removal have struggled to identify the right patients. There is significant clinical heterogeneity of the innate immune response across patients with sepsis. In contrast, targeted EBP therapies, which involve measuring a single solute, then choosing appropriate therapy to target its removal, allow for the specific selection of a suitable patient. Unfortunately, measuring the target can prove challenging. Endotoxin can be measured in whole blood using the endotoxin activity assay. However, owing to the size of intact endotoxin molecule, it cannot be filtered using hemofiltration membranes. Adsorption, which only requires the contact of blood or plasma with a sorbent, is therefore a suitable model to target its removal. TREA technologies include devices that specifically target endotoxin (Alteco LPS Adsorber, MATISSE adsorber, Toraymyxin 20R, Toxipak sorption column) and those for which endotoxin removal is included in a more broad-spectrum device (Efferon LPS, oXiris).</p><p><strong>Key messages: </strong>While only a small number of devices are currently available in the TREA class of EBP, there is an opportunity here to bring precision medicine to sepsis.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of hypoalbuminemia with the risk of peritoneal dialysis-associated peritonitis in peritoneal dialysis patients: a meta-analysis.","authors":"Danfeng Zha, Xionghao Yang, Huiqin Xi","doi":"10.1159/000543693","DOIUrl":"https://doi.org/10.1159/000543693","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this meta-analysis was to assess the association between hypoalbuminemia and the risk of peritoneal dialysis-associated peritonitis (PDAP) in patients receiving peritoneal dialysis (PD).</p><p><strong>Methods: </strong>By the specified deadline of November 13, 2023, a systematic search across various databases was conducted to identify relevant literature. The databases searched included PubMed, Embase, the Cochrane Library, Web of Science, the China National Knowledge Infrastructure (CNKI), WanFang, and VIP. The effect sizes were quantified using odds ratios (OR) or hazard ratios (HR) and were presented with 95% confidence intervals (CI). The analysis was stratified by the type of PD [continuous ambulatory peritoneal dialysis (CAPD), mixed] and the timing of albumin (ALB) level measurements (at baseline, after initiation of PD, or average over time).</p><p><strong>Results: </strong>A total of 14 studies encompassing 6,448 PD patients were incorporated in this meta-analysis. The findings revealed a significantly elevated risk of peritonitis in patients with hypoalbuminemia compared to those with an ALB level above 3.5g/dL (OR: 2.70, 95% CI: 1.78 to 4.09, P <0.001). Stratification by PD modality showed consistent results within the CAPD group (OR: 5.79, 95% CI: 3.57 to 9.41, P <0.001). For the timing of ALB measurements, the baseline measurement group maintained these findings (OR: 2.53, 95% CI: 1.40 to 4.58, P =0.002), while the group with post-PD measurements did not show statistical significance (OR: 0.76, 95% CI: 0.49 to 1.17, P =0.212). The HR analysis similarly indicated an increased risk of peritonitis in hypoalbuminemia patients compared to those with higher serum ALB levels (HR: 1.62, 95% CI: 1.44 to 1.82, P <0.001).</p><p><strong>Conclusion: </strong>Our meta-analysis reveals that hypoalbuminemia raises the risk of peritonitis in PD patients, particularly at baseline. This finding underscores the need for close monitoring to detect peritonitis early. Further research is needed to understand the impact of ALB levels post-PD initiation on peritonitis risk.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-23"},"PeriodicalIF":2.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation Strategies for Continuous Renal Replacement Therapy in France: A Survey of Practices.","authors":"Justine Pible, Frank Bidar, Nicolas Chardon, Valérie Cerro, Carole Ichai, Céline Monard, Antoine Schneider, Olivier Joannes-Boyau, Jean-Michel Constantin, Thomas Rimmelé","doi":"10.1159/000540553","DOIUrl":"10.1159/000540553","url":null,"abstract":"<p><strong>Introduction: </strong>Anticoagulation for continuous renal replacement therapy (CRRT) can be performed using systemic anticoagulation or regional citrate anticoagulation (RCA). The 2012 Kidney Disease Improving Global Outcomes guidelines support the use of RCA as the first-line strategy in patients requiring CRRT, with and without bleeding risk. Implementing RCA in the intensive care unit (ICU) implies involving all medical and nursing staff. The primary objective of this study was to report and describe the various anticoagulation strategies for CRRT in French ICUs. The secondary objectives were to determine the rate of RCA use and to identify the factors limiting its implementation.</p><p><strong>Methods: </strong>An online questionnaire containing 40 questions was sent to attending physicians and fellows practicing in French ICUs between May and September 2021. The questionnaire was sent via several networks: mailing list from the French Society of Anesthesia and Intensive Care Medicine and mailing lists of RRT manufacturers.</p><p><strong>Results: </strong>A total of 597 responses were analyzed. RCA was used by most of the participants for patients with (81%) and without (80%) increased bleeding risk. The preferred CRRT modality of the participants while using RCA was continuous veno-venous hemodialysis (48%). The clinical situations frequently reported as an absolute contraindication to RCA were uncontrolled shock associated with liver failure and drug poisoning impairing citrate metabolism (62% and 52%, respectively). In case of a higher risk of citrate accumulation, most participants claimed to perform closer biological monitoring (57%) or to modify the CRRT protocol (61%). Among the participants who did not prescribe RCA as a first-line strategy, the main factors limiting its implementation were the lack of nurse (50%) or physician (34%) training.</p><p><strong>Conclusion: </strong>RCA is the main anticoagulation strategy prescribed for CRRT in France. Providing medical and nursing staff easy access to training may facilitate the understanding and use of RCA as the first-line anticoagulation strategy for CRRT.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"e-Prescribing, Charting, and Documentation for Continuous Renal Replacement Therapy: A Green Intensive Care Unit and Nephrology Initiative.","authors":"Ian Baldwin, Jian Wen Chan, Stuart Downs, Connor Palmer","doi":"10.1159/000541487","DOIUrl":"10.1159/000541487","url":null,"abstract":"<p><strong>Background: </strong>Patient care informatics are becoming more advanced with digital capacity and server functionality. The intensive care unit (ICU) is becoming paperless for prescribing, charting, and monitoring care. A further challenge is to include all life sustaining therapies in this digital space. Digital modules and options may be available; however, continuous renal replacement therapies (CRRTs) often require custom design for many nuances. Associated with the COVID pandemic and a surge in the paperless and \"green\" ICU bedside, we gathered a team to design, develop, and implement a CRRT orders, charting-documentation, and monitoring functionality into our existing Cerner (ORACLE Corp., Austin, Texas, USA) software.</p><p><strong>Key messages: </strong>This included new approaches to the two-dimensional paper documents used prior and a live dashboard with new metrics and data. The design linked to other relevant CRRT pages such as the master patient fluid balance, pathology results, and medication prescribing. The primary views and function are role-related for medical, nursing, and pharmacy with specific and sensitive input. Following the build and implementation, initial evaluation was positive and led to an audit trail or e-history for prescribers use and provision for concurrent therapies. Clinicians use this digital ordering differently with live data available for \"handover\" and case discussion. There is scope for research and further links to devices such as personal phones and via an app.</p><p><strong>Summary: </strong>This experience may assist CRRT users design and develop similar prescribing, charting, and monitoring bedside computer opportunities in the desire for digital and green nephrology in the ICU.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"18-27"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dialysis Vintage Is Partially Associated with Sarcopenia in Patients on Hemodialysis.","authors":"Dario R Mondini, Marvery P Duarte, Maryanne Zilli Canedo Silva, Henrique Santos Disessa, Maristela Bohlke, Angélica N Adamoli, Rodrigo R Krug, Maria C K Panno, Daiana C Bundchen, Luiz A R Medina, Antônio J Inda-Filho, Jacyara Santos de Oliveira, Barbara P Vogt, Maycon M Reboredo, Marco C Uchida, Heitor S Ribeiro","doi":"10.1159/000545258","DOIUrl":"10.1159/000545258","url":null,"abstract":"<p><strong>Introduction: </strong>Dialysis-related factors may contribute to sarcopenia, but this has yet to be explored. We investigated the association between dialysis vintage and sarcopenia in patients on hemodialysis.</p><p><strong>Methods: </strong>This cross-sectional analysis is part of the SARC-HD study. Sarcopenia was assessed according to the revised EWGSOP2 criteria using handgrip strength and calf circumference measurements. We considered sarcopenia as confirmed and severe stages. Patients were stratified into groups according to the quintiles of dialysis vintage months: 3-11; 12-24; 25-43; 44-76; and ≥77. The 12-24 months group was adopted as reference in adjusted binary logistic regressions.</p><p><strong>Results: </strong>A total of 983 patients from 19 dialysis centers were included (67% male, median age 59 years). The median dialysis vintage was 33 months (interquartile range: 14-67), 31% were receiving hemodiafiltration, and 29% had a short daily weekly frequency (≥4 sessions/week). Probable sarcopenia was found in 12%, confirmed in 9%, and severe in 5%. Probable sarcopenia was higher in the 3-11 months group (p = 0.045). In the overall analysis, no significant association was found between dialysis vintage and sarcopenia. However, in sensitivity exploratory analyses excluding patients on hemodiafiltration, the shortest (adjusted odds ratio [aOR] = 2.95, 95% confidence interval [CI]: 1.24-7.00) and longest (aOR = 3.02, 95% CI: 1.22-7.44) dialysis vintage groups showed higher odds of sarcopenia compared to the 12-24 months group. A similar pseudo-U-shaped association was found among patients on conventional weekly frequency (excluding short daily), where the shortest (aOR = 2.88, 95% CI: 1.23-6.74) and longest (aOR = 2.77, 95% CI: 1.17-6.55) dialysis vintage groups were associated with higher odds of sarcopenia.</p><p><strong>Conclusion: </strong>The association between dialysis vintage and sarcopenia was observed in conventional hemodialysis regimens. This association seems to be pseudo-U-shaped in the shortest and longest dialysis vintage groups. Future studies should examine how pre-dialysis care and dialysis regimens affect sarcopenia development or progression.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"357-363"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diluted Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Pediatric Patients: A Systematic Review and Suggested Practice Points.","authors":"Sidharth Kumar Sethi, Ashita Tolwani, Omer S Ashruf, Mihika Aggarwal, Girish Chandra Bhatt, Aishwarya Nair, Kritika Soni, Savita Savita, Shyam Bihari Bansal, Khalid Alhasan, Timothy Bunchman, Rupesh Raina, Sidharth Kumar Sethi","doi":"10.1159/000545674","DOIUrl":"10.1159/000545674","url":null,"abstract":"<p><strong>Introduction: </strong>Continuous renal replacement therapy (CRRT) is increasingly used in critical pediatric patients with acute kidney injury (AKI). The choice of anticoagulant is vital to minimize circuit clotting and bleeding complications. Regional citrate anticoagulation (RCA) is preferred for its safety profile, particularly in critically ill pediatric patients who are susceptible to bleeding.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted using PubMed, Google Scholar, and Cochrane databases following PRISMA guidelines. Keywords included \"diluted citrate,\" \"regional citrate anticoagulation,\" \"continuous renal replacement therapy,\" \"pediatrics,\" and \"adverse effects.\" Studies were included if they involved neonates and pediatric patients, reported citrate concentration, and safety and efficacy outcomes of RCA in CRRT. Data were extracted on study characteristics, citrate concentration, circuit lifespan, metabolic and electrolyte disturbances, and other adverse effects.</p><p><strong>Results: </strong>A total of 16 studies met the inclusion criteria. RCA was associated with fewer clotting events and a longer median circuit life compared to heparin. However, complications such as metabolic alkalosis, hypocalcemia, and hypernatremia were noted. In our single-center experience, dilute citrate anticoagulation was used in 16 pediatric patients undergoing CRRT, showing promising results with reduced clotting and prolonged circuit life. The modified pediatric citrate protocol presented aims to address complications by using a diluted citrate solution.</p><p><strong>Conclusions: </strong>RCA is effective in prolonging circuit life and reducing clotting in pediatric CRRT. The modified pediatric citrate protocol presents a safer alternative by reducing the risk of metabolic and electrolyte disturbances. Ongoing monitoring of calcium and electrolyte levels is essential to mitigate potential complications. This protocol may standardize RCA use in pediatric CRRT, improving safety and outcomes for critically ill children with AKI.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"455-473"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertonic Citrate Solution Protocol Associated with Longer Filter Lifetime in Critically Ill Patients Requiring Continuous Kidney Replacement Therapy.","authors":"Anyarin Wannakittirat, Khanittha Yimsangyad, Nuttha Lumlertgul, Sadudee Peerapornratana, Nattachai Srisawat","doi":"10.1159/000546579","DOIUrl":"10.1159/000546579","url":null,"abstract":"<p><strong>Introduction: </strong>Regional citrate anticoagulation (RCA) serves as the first line of anticoagulants in continuous kidney replacement therapy (CKRT). Premature circuit clotting is associated with increased workload, costs, and adverse patient outcomes. Current evidence shows limited studies on the relationship between RCA protocols and circuit clotting in RCA CKRT. The study aimed to investigate the factors influencing filter lifetime that lead to premature circuit clotting, including citrate formulas employed during RCA in CKRT.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at a single center and included patients receiving CKRT from February 2023 to September 2023. The primary outcome was the identification of factors associated premature circuit clotting. Secondary outcomes included circuit ionized calcium levels, citrate doses, blood transfusions, citrate formulations, and other variables that may impact filter clotting.</p><p><strong>Results: </strong>A total of 199 filters from 97 patients were analyzed in this study. After exclusion of circuit termination due to non-clotting event, 38 filters experienced premature circuit clotting (lifetime ≤72 h), while 70 filters clotted after 72 h. The baseline characteristics and clinical outcomes were well balanced between the groups. In the multivariable analysis, only isotonic citrate formulations (RR 2.45, 95% CI: 1.17-5.14, p = 0.018) and corrected citrate doses (RR 0.48, 95% CI: 0.27-0.87, p = 0.016) exhibited statistically significant associations with filter premature clotting.</p><p><strong>Conclusion: </strong>Different RCA prescriptions may affect filter lifetime and circuit integrity. Notably, the hypertonic RCA protocol was associated with a significantly longer filter lifetime compared to the isotonic RCA protocol. However, additional data from rigorously constructed randomized controlled trials are needed.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"373-383"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Your Kidneys OK? Detect Early to Protect Kidney Health.","authors":"Joseph A Vassalotti, Anna Francis, Augusto Cesar Soares Dos Santos, Ricardo Correa-Rotter, Dina Abdellatif, Li-Li Hsiao, Stefanos Roumeliotis, Agnes Haris, Latha A Kumaraswami, Siu-Fai Lui, Alessandro Balducci, Vassilios Liakopoulos","doi":"10.1159/000546512","DOIUrl":"10.1159/000546512","url":null,"abstract":"","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"524-532"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Use of Kidney Replacement Therapy and Temporary Left Ventricular Assist Device in Cardiogenic Shock: A Systematic Review and Meta-Analysis.","authors":"Oliver Lim, Kamalesh Anbalakan, Ryan Ruiyang Ling, Bryan Tan, Vivien Mak, Ying Chen, Manish Kaushik, Matthew Jose Chakaramakkil, Kollengode Ramanathan","doi":"10.1159/000546854","DOIUrl":"10.1159/000546854","url":null,"abstract":"<p><p><p>Introduction: The use of temporary-left ventricular assist devices (T-LVADs) for circulatory support in cardiogenic shock is increasing along with complications like acute kidney injury requiring kidney replacement therapy (KRT). While KRT is linked to mortality in cardiogenic shock, data on mortality in patients receiving both T-LVAD and KRT are limited.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis, searching three databases from inception through December 30, 2023, for studies reporting on patients with concurrent T-LVAD and KRT support during cardiogenic shock. We performed random-effects meta-analyses, looking at in-hospital mortality as our primary outcome. Subgroup analysis was performed based on the continent, timing of KRT, and type of T-LVAD. Risk of bias was assessed with the Joanna Briggs Institute checklists and certainty of evidence with the GRADE approach.</p><p><strong>Results: </strong>We included 35 studies after screening through 89 full-text articles, consisting of 2,277 individuals receiving T-LVAD and 722 (30.9%, 95% CI: 25.8-36.6) receiving concurrent KRT. In-hospital mortality was pooled across 6 studies, with 91 non-survivors (65.5%) among 139 individuals (95% CI: 57.2-72.9). Concurrent KRT and T-LVAD was associated with higher in-hospital (OR 3.48, 95% CI: 2.20-5.49) and overall mortality (OR 2.19, 95% CI: 1.01-4.76) compared to patients not on KRT. The proportion of patients on KRT was significantly (p interaction = 0.0004) larger in Europe (37.2%, 95% CI: 32.2-42.4) than North America (18.2%, 95% CI: 12.0-26.7). Region, type of T-LVAD, and publication year did not significantly impact any of the mortality outcomes.</p><p><strong>Conclusion: </strong>Patients on concurrent KRT and T-LVAD suffer significantly greater odds of mortality compared to patients not receiving KRT during their hospital admission. A substantial proportion of patients receiving T-LVADs require KRT. Further studies with head-to-head comparisons between KRT and non-KRT treatment arms are warranted to confirm our findings, in addition to identifying at-risk populations that require KRT and potential interventions to improve survival in this subset of patients. </p>.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"497-512"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on Water Utilization in Hemodialysis: Nephrologists' Responsibilities.","authors":"Rahul Abraham, David S Goldfarb, David Goldfarb","doi":"10.1159/000546034","DOIUrl":"10.1159/000546034","url":null,"abstract":"<p><strong>Background: </strong>Hemodialysis is a water-intense procedure, needing large quantities of water for preparation of small volumes of dialyzate. The resulting large volumes of reject water are usually discarded. With the rising water crisis both in the USA and the world, it is essential to understand water utilization and identify ways to minimize its utilization and maximize the use of the reject water.</p><p><strong>Summary: </strong>Unfortunately, water from the city sources cannot be used to produce dialyzate unless it undergoes further purification. This results in a large amount of reject water, which can be from 50 to 70% of total water use, resulting in an enormous waste of resources. A review of solutions for water sustainability is broadly classified into solutions that decrease water utilization and solutions for increased reject water utilization. Those that are aimed at decreasing water utilization were mainly based in innovations in technology - examples are NxStage PureFlow™SL, Aquaboss by Braun and AquaBPlus by Fresenius, and those that focused on increased reuse of RO reject water rely on data that it can be safely utilized for various purposes such as irrigation and flushing toilets. These strategies can be cost-effective. Although the need for sustainability has been recognized, there needs to be further awareness and participation among nephrologists to further this cause. In addition, there need to be policies put forward by the government that could encourage sustainability.</p><p><strong>Key messages: </strong>Hemodialysis continues to heavily tax the environment. Although the need for sustainability has been recognized, there still remains a lot of work that needs to be done. Further buy-in is needed from all participating entities - nephrologists, dialysis manufacturers and organizations, and the government in order to safeguard our limited resources.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"447-454"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}